- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04892823
Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors
Accelerated Biological and Phenotypic Aging in Hematopoietic Cell Transplant Survivors: Social Support as a Protective Factor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Examine associations between social support, strain, and isolation and phenotypic aging over the 1-year recovery period.
II. Examine associations between social support, strain, and isolation and biological aging over the 1-year recovery period.
III. Test biological aging as a mediator linking social processes and phenotypic aging.
EXPLORATORY OBJECTIVE:
I. Test sex differences in Aims 1 and 2.
OUTLINE:
Adopting a prospective design, participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives16. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome-wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Medical College of Wisconsin Cancer Center Clinical Trials Office
- Phone Number: 8900 866-680-0505
- Email: cccto@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert Hospital and the Medical College of Wisconsin
-
Contact:
- Kelly Rentscher, PhD
- Phone Number: 414-955-8990
- Email: krentscher@mcw.edu
-
Principal Investigator:
- Kelly Rentscher, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18 years and older who are competent to give their informed consent.
- Ability to read, speak, and understand English.
- Received a hematopoietic cell transplant within the previous 100 days.
Exclusion Criteria:
- Less then Aged 18 years and older who are competent to give their informed consent.
- Cannot read, speak, and understand English.
- Has not received a hematopoietic cell transplant within the previous 100 days.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Supportive care (EAR, questionnaires, biospecimen collection)
Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives.
At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing.
Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
|
Complete questionnaires
Undergo collection of blood sample
Review of medical records
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Associations between social support, strain, and isolation and phenotypic aging
Time Frame: through study completion, an average of 1 year
|
Multiple regression models will examine subjective and objective measures of each social process as separate predictors of change in phenotypic aging over the 1-year period, accounting for covariates.
|
through study completion, an average of 1 year
|
Associations between social support, strain, and isolation and biological aging
Time Frame: through study completion, an average of 1 year
|
Raw gene expression data will be quantile-normalized and log2-transformed.
Similar to Aim 1, multiple regression models will examine each social process as separate predictors of change in cellular senescence marker p16INK4a over the 1-year period, accounting for covariates.
Mixed linear models will examine associations between each social process and deoxyribonucleic acid damage response (DDR) and senescence-associated secretory phenotype (SASP) gene profiles, estimated by maximum likelihood to account for systematic differences across genes by treating them as repeated measurements with an unstructured covariance matrix.
Bioinformatics analyses will use regression models to identify genes with > 1.5-fold difference.
|
through study completion, an average of 1 year
|
Biological aging as a mediator linking social processes and phenotypic aging
Time Frame: through study completion, an average of 1 year
|
A regression-based mediation approach will examine biological aging (p16INK4a messenger ribonucleic acid, DDR and SASP composites) as mediating variables in associations between each social process and change in phenotypic aging, using the PROCESS macro for SPSS statistical software.
|
through study completion, an average of 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sex differences
Time Frame: through study completion, an average of 1 year
|
Multiple regression models will examine interactions between social support, strain, and isolation and biological sex as separate predictors of biological (Aim 1) and change in phenotypic (Aim 2) aging, accounting for covariates.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kelly Rentscher, PhD, Medical College Of Wisconsin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 43000 (Other Identifier: Medical College of Wisconsin)
- NCI-2021-02616 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- K01AG065485 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden